-- Organization saw growth in AD Workbench users, data partners, and patient 
datasets from across the globe, including from low- and middle-income 
countries  

Today, the Alzheimer's Disease Data Initiative (ADDI) marked one year of 
transforming how Alzheimer's disease and related dementias will be treated by 
significantly increasing access to data from academic institutions, 
government-sponsored organizations, pharmaceutical companies, and others 
dedicated to data sharing and collaboration. 

Logo - https://mma.prnewswire.com/media/1335810/ADDI_Logo.jpg 

"One year ago, ADDI took our first steps on the path to tackling the hard 
problems of data access in Alzheimer's research in close collaboration with 
partners who share our vision," said Executive Director Tetsuyuki Maruyama. "We 
started by dedicating the resources needed to build a platform that breaks down 
barriers so that the research community can access, analyze, store and share 
the data needed to accelerate progress on treating and curing Alzheimer's 
disease. The progress ADDI and our partners have made in such a short amount of 
time is inspiring."

Since its launch last year, ADDI's cloud-based Alzheimer's Disease (AD) 
Workbench has built a community of over 2,000 users in 80 countries, who have 
created more than 200 workspaces with access to over 35 datasets, many of which 
include data from diverse populations around the world. Researchers can also 
bring their own data into a secure workspace to analyze and make connections 
across multiple datasets. The trove of data available on the AD Workbench at no 
cost to registered users includes observational clinical trials, synthetic 
cohort studies, and synthetic brain images, all accessible in a secure and 
centralized location that allows researchers to explore freely field-level 
metadata and investigate datasets. 

In addition to these milestones, ADDI also celebrated the following 
achievements:

    - The first European data partner, the European Prevention of Alzheimer's 
      Dementia (EPAD) Consortium, which includes their first academic partner
      – the University of Edinburgh. 
    - The first major industry partnership with Eli Lilly and Company (Lilly), 
      which shared their GERAS-EU study dataset. This was later followed by 
      three other GERAS studies that now include data from seven countries 
      (France, Germany, Italy, Japan, Spain, the United Kingdom, and the 
      United States). 
    - Access to 19 new datasets from Lilly and GlaxoSmithKline (GSK) through 
      a partnership with Vivli and interoperability with the Vivli platform. 
    - The first data sharing partner in Asia, the Indian Institute of Science 
      Centre for Brain Research, which will provide federated access through 
      the AD Workbench to home visit data. 

"The success of our Data Science Challenge substantially increased user 
engagement on our platform and the introduction of data sharing capability in a 
federated manner effectively addressed data contributors' requirement to be 
able to share data securely and remotely," said Mukta Phatak, Director of Data 
Science at ADDI. "The AD Workbench will continue to expand and evolve with the 
addition of new datasets, analysis tools, and other products and services to 
meet the needs of the research community who are working to find treatments and 
cures for this disease."

ADDI is currently in the process of adding more than 15 additional datasets in 
the next year. They also plan to expand their data sharing community into a 
gateway where researchers, data providers, and the broader Alzheimer's and 
related dementia community can come together to share ideas, post questions, 
and offer tools or resources that further efforts to find answers to shared 
challenges. 

For more information please visit: www.Alzheimersdata.org

Alzheimer's Disease Data Initiative (ADDI), a 501 (c)(3) medical research 
organization (MRO) in partnership with the University of Washington, is 
dedicated to advancing scientific breakthroughs in the treatment of Alzheimer's 
disease and related dementias. ADDI aims to increase interoperability of 
existing data platforms globally, increase sharing of dementia-related data 
from academic and industry sources, and empower scientists to find, search, 
combine, and analyze data that could lead to new discoveries in dementia 
research. ADDI also aims to enhance or fill gaps in datasets, including 
enabling the generation of more demographically representative datasets.

LinkedIn: AlzheimersData ( 
https://c212.net/c/link/?t=0&l=en&o=3359495-1&h=2035512282&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Falzheimersdata%2F&a=AlzheimersData 
) Twitter: AlzData ( 
https://c212.net/c/link/?t=0&l=en&o=3359495-1&h=386413442&u=https%3A%2F%2Ftwitter.com%2FAlzData&a=AlzData 
)

SOURCE: Alzheimer’s Disease Data Initiative (ADDI)

CONTACT: Eric Conrad, +1 (202) 813-4815 | eric.conrad@gmmb.com